Reckitt Benckiser Faces Generic Threats After FDA Rejection

Reckitt Benckiser Group Plc faces competition in pharmaceuticals for the first time after the U.S. Food and Drug Administration approved two generic variants of its Suboxone heroin-dependency drug, thwarting the company’s attempts to keep rivals away from its most profitable business.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.